Extensive analysis of signaling pathways in breast cancer-proposal of a new classification based on activity of signaling pathways
| Project/Area Number |
22501055
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Japanese Foundation For Cancer Research |
|---|
Principal Investigator |
HORII Rie 公益財団法人がん研究会, がん研究所病理部, 研究員 (20446272)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
AKIYAMA Futoshi 公益財団法人がん研究会, がん研究所病理部, 臨床病理担当部長 (50222550)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 分子標的治療 / 生存増殖シグナル伝達系 / 乳癌 / バイオマーカー / プロファイリング解析 |
|---|
| Research Abstract |
The activation of proliferative signaling pathways is one of the causes of carcinogenesis and several drugs interfering with these pathways are currently being developed. We evaluated 338 invasive breast cancer patients by focusing attention on six factors, p-AKT, Cyclin D1, P27, p-p70S6K, p-4EBP1 and p-MAPK/ERK, in the signaling pathways. These factors were immunohistologically examined and using those results a new breast cancer classification was devised. The new classification was significantly related to conventional clinicopathological characteristics. This classification reflects the activation status of the signaling pathways and useful for selection of newly developed drugs that interfere with signaling pathways
|
Report
(4 results)
Research Products
(5 results)
